Pharming Group (NASDAQ:PHAR - Get Free Report) saw a significant drop in short interest in May. As of May 15th, there was short interest totalling 1,300 shares, a drop of 18.8% from the April 30th total of 1,600 shares. Based on an average trading volume of 5,100 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company's stock are sold short.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Oppenheimer increased their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 20th.
Get Our Latest Analysis on PHAR
Pharming Group Stock Performance
Shares of PHAR traded up $0.93 during trading hours on Wednesday, reaching $12.16. 4,721 shares of the company's stock traded hands, compared to its average volume of 6,465. The firm has a market capitalization of $827.26 million, a price-to-earnings ratio of -46.77 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. Pharming Group has a twelve month low of $6.65 and a twelve month high of $12.55. The business's fifty day simple moving average is $9.06 and its two-hundred day simple moving average is $8.94.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The firm had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Analysts predict that Pharming Group will post -0.2 earnings per share for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
